MabVax Therapeutics Receives Two Small Business Technology Transfer Program Awards From The National Cancer Institute

December 18, 2008

SAN DIEGO, Dec. 18 /PRNewswire/ — MabVax Therapeutics Inc., a privately held immunotherapeutics discovery and development company focused on the development and commercialization of novel immunotherapies for the treatment of cancer, announced the company has received two grant awards from the National Cancer Institute under the Small Business Technology Transfer Program (STTR) totaling $400,000. The first award is aimed at supporting a Pilot Trial With a Tetravalent Conjugate Vaccine Against Small Cell Lung Cancer. The second award is aimed at the generation of Human Monoclonal Antibodies from Immunized Patients.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080812/LATU515LOGO)

Earlier this year, MabVax completed two licensing agreements with Sloan-Kettering Institute for Cancer Research, the research arm of Memorial Sloan-Kettering Cancer Center (MSKCC), for exclusive development and commercialization rights to multiple vaccines against selected recurrent cancers. MSKCC has already initiated Phase I clinical trials with two different vaccines to demonstrate immunogenicity and tolerability in sarcoma and breast cancer. The first STTR award will support work on a Phase I small cell lung cancer trial to be conducted by MSKCC early next year, with MabVax providing laboratory analysis support. The second STTR award will support MabVax’s efforts to isolate human antibodies from immunized patients participating in those Phase I trials.

“The STTR awards will offset early expenses that both MSKCC and MabVax will incur as we continue to execute our plans to initiate MabVax sponsored Phase II cancer vaccine clinical trials in sarcoma and small cell lung cancer in the coming year. MabVax will simultaneously build a pipeline of fully human monoclonal antibody products against each of the antigenic targets utilized in the vaccines,” said David Hansen the company’s President and Chief Executive Officer. MabVax is working to address a significant unmet medical need, to prevent recurrence in certain types of cancers and prolong patient survival, by targeting residual circulating cancer cells and micrometastasis with passively administered or vaccine induced antibodies.

About MabVax Therapeutics, Inc.

MabVax was formed to commercialize the work of Dr. Phil Livingston and colleagues at MSKCC who over the last 25 years have developed cancer vaccines against ten distinct antigenic targets on various types of cancer cells. These vaccines target gangliosides and other carbohydrate antigens that are the most extensively expressed antigenic targets on the cell surface of certain cancers. Vaccines, or passively administered antibodies developed from these vaccines, produced evidence demonstrating the prevention of tumor recurrence and prolonged survival in preclinical models and supporting data in early Phase I human clinical trials. The company is initially focused on developing polyvalent vaccines and a pipeline of fully human monoclonal antibodies to treat a variety of cancers including sarcoma, small cell lung cancer, ovarian cancer, and melanoma. MabVax closed a Series A venture financing with GBP Capital in late February 2008.

SOURCE MabVax Therapeutics Inc.

Source: newswire

comments powered by Disqus